



The Lambert-Eaton
LEMS Family Association

Global Access to Amifampridine for LEMS

Information reviewed August 2026

Purpose

This document identifies countries or regions where FIRDAPSE / amifampridine approval or current market availability has been verified from authoritative sources.



Verified approval / current market listing

● United States¹ ● Canada² ● European Union³ ● United Kingdom⁴ ● Japan⁵

Interpretation

An unmarked country should not be interpreted as proof that amifampridine is unavailable. Access may differ through national approvals, local products, clinical programs, hospital supply, or special-access pathways that have not yet been verified for this document.

References

1. U.S. FDA. FIRDAPSE (amifampridine) Prescribing Information, NDA 208078; current label.
2. Health Canada Drug Product Database. FIRDAPSE, DIN 02502984; status: Marketed; product monograph dated June 10, 2025.
3. European Medicines Agency. Firdapse (amifampridine), EPAR; EU marketing authorisation for symptomatic treatment of adult LEMS.
4. electronic Medicines Compendium (UK). FIRDAPSE 10 mg tablets, Summary of Product Characteristics; updated March 24, 2026.
5. DyDo Pharma, Inc. FIRDAPSE Tablets 10 mg (amifampridine phosphate): Japanese approval Sept. 24, 2024; sales launched Jan. 21, 2025.

Medical information disclaimer

The Lambert-Eaton LEMS Family Association has diligently researched the information presented for accuracy and timeliness. However, this material is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The Association cannot be responsible for decisions made or actions taken based on this information. Patients are encouraged to consult with and coordinate their care through their healthcare team.